Algeta

Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, MSD, Ovarian cancer, Mirati Therapeutics, London Business School, University of Coimbra, GSK, BMS, Doctor of Philosophy, Therapy, Algeta, Colorectal cancer, International, Pharmacy, Radiopharmaceutical, Radium-223, Agios Pharmaceuticals, Amgen, Cubist Pharmaceuticals, Takeda Pharmaceutical Company, Bristol Myers Squibb, University, Private sector, The central science, Drug development, Sanofi, Psychiatry, BASF, Master of Science, M.B.A, Science, GE HealthCare, Pharmaceutical industry

“We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.

Key Points: 
  • “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.
  • “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs.
  • Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals.
  • In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board.

bit.bio Strengthens Leadership Team With Appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations

Retrieved on: 
Monday, June 12, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Corporate Affairs, Canaccord Genuity, University, Senior, Communication, Multimedia, Bachelor of Science, Regenerative medicine, Doctor of Philosophy, Division, Dynamics (music), Corporation, Drug discovery, CFO, Growth, Foreign policy, UBS, Bank, Synthetic biology, Management, Algeta, Psychology, Neuroscience, Incyte, Atlantic Ocean

bit.bio, the cell coding company, today announces the appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations.

Key Points: 
  • bit.bio, the cell coding company, today announces the appointment of Dr Michael Booth as Senior Vice President, External Affairs and Investor Relations.
  • Dr Booth joins bit.bio from Crescendo Biologics where he was responsible for financial strategy and reporting as well as global investor relations and communications.
  • Dr Booth brings over 20 years’ experience in the capital markets, including leadership roles in investor relations and financial communications, making him a valuable addition to the bit.bio team.
  • Dr Michael Booth was most recently CFO at Crescendo Biologics where he was responsible for financial strategy and reporting as well as for global investor relations and communications.

MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Pharmaceutical, Health, Oncology, MBA, Medicine, Therapy, Genzyme, Atlas Venture, Acquisition, Bayer, Georgetown University, Food, Investigational New Drug, MOMA, ATPase, FDA, Knowledge, Hematology, Regulation of tobacco by the U.S. Food and Drug Administration, Atlas, Cancer, IND, Pharmaceutical industry, Management, Indiana University, Algeta

MOMA Therapeutics, a biopharmaceutical company discovering a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointment of Jeff Albers as independent chairperson of the company’s board of directors.

Key Points: 
  • MOMA Therapeutics, a biopharmaceutical company discovering a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointment of Jeff Albers as independent chairperson of the company’s board of directors.
  • “Jeff is a seasoned industry leader who is widely recognized for his strategic thinking, humility and breadth of experience,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA.
  • “I am excited to partner with MOMA during this critical phase of the company’s evolution,” said Mr. Albers.
  • Mr. Albers is currently board chairman of Blueprint Medicines and sits on the board of directors of Kymera Therapeutics and Magenta Therapeutics; he is also a venture partner at Atlas Ventures and serves on the board of advisors for Life Sciences Cares.

Nordic Nanovector ASA Announces Proposed Board Changes - Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors

Retrieved on: 
Wednesday, April 6, 2022
Company, CD37, USD, Marketing, Board, Doctor of Philosophy, Committee, Publication, Centre for Educational Measurement at the University of Oslo, Workload, HealthCap, Board of directors, Acquisition, OSE, Master of Science, Prostate cancer, Time, Institute, Bangladesh Technical Education Board, FDA, IPO, University, AGM, Online gambling, Pharmaceutical industry, Algeta, Bayer

In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer.

Key Points: 
  • In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer.
  • Jan H. Egberts, M.D., Chairman of Nordic Nanovector's Board of Directors, said: "We are delighted to have Dr Ramdahl join our Board.
  • While HealthCap remains a highly supportive investor in Nordic Nanovector, I believe it is time for me to step down from the Board and I am delighted that Dr Thomas Ramdahl has accepted to be nominated to join as a Director.
  • I know Thomas well from his time with Algeta and I am confident that he will be an important contributor to Nordic Nanovector's future development."

Blueprint Medicines Elevates Two Talented Leaders to its Executive Team

Retrieved on: 
Thursday, January 20, 2022
Research, Corporate development, Agios Pharmaceuticals, LinkedIn, Private Securities Litigation Reform Act, SEC, Ipsen, Hotel manager, Science, NASDAQ, BPMC, Massachusetts Institute of Technology, Development, Nomination, U.S. Securities and Exchange Commission, Therapy, Cancer, Yale University, Business development, Publication, Corporation, Algeta, COVID-19, Safety, Risk, University of California, University, Disease, Marketing, Multimedia, Cell biology, Annual report, Patient, Precision medicine, Growth, Roche, Leadership, Grade (consulting), Degenerative disease, Acquisition, Sanofi, View, Goal, Patent, Twitter, Lung cancer, Security (finance), Senior, Public relations, Management, Pharmaceutical industry, Genzyme, Biochemistry, Blueprint

CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ --Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two executive leadership changes highlighting the company's commitment to developing exceptional leaders.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 20, 2022 /PRNewswire/ --Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two executive leadership changes highlighting the company's commitment to developing exceptional leaders.
  • "I'm thrilled to announce the elevation of these two talented and dedicated Blueprint Medicines colleagues," said Jeff Albers, Chief Executive Officer, Blueprint Medicines.
  • Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.
  • Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Oncoinvent Strengthens Leadership Team

Retrieved on: 
Monday, October 4, 2021
Oncology, Health, Clinical Trials, General Health, Radiology, Pharmaceutical, Transfer, Clinical trial, Radiation, Oncology, Novartis, Radionuclide, Drug, Regulatory affairs, ASA, MD, LET, Algeta, Consultant, Medtech, Alpha, Linear energy transfer, Knowledge, Ovarian cancer, Chief Medical Advisor to the President, Karolinska Institute, Drug development, Colorectal cancer, Roche Diagnostics, Clinical research, Doctor of Philosophy, Pharmaceutical industry, Medicine, Medical imaging, Radspherin®, Oncoinvent, RADSPHERIN®, ONCOINVENT

Dr. Myren comes to Oncoinvent from Photocure ASA where she held the position of Vice President Global Medical Affairs and Clinical Development.

Key Points: 
  • Dr. Myren comes to Oncoinvent from Photocure ASA where she held the position of Vice President Global Medical Affairs and Clinical Development.
  • I am very pleased that we have been able to attract such qualified and experienced people such as Kari, Anne-Kirsti, and Stian to our team, said Jan A. Alfheim, Chief Executive Officer of Oncoinvent.
  • I am looking forward to working with them to build Oncoinvent into a world leader in alpha-emitting radiotherapeutics.
  • Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers.

Crescendo Biologics Further Strengthens Leadership Team With Appointment of Dr Michael Booth as Chief Financial Officer

Retrieved on: 
Monday, May 10, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Life sciences, Biotechnology, Health sciences, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Cancer immunotherapy, Algeta

b'Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointment of Dr Michael Booth as Chief Financial Officer (CFO).

Key Points: 
  • b'Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointment of Dr Michael Booth as Chief Financial Officer (CFO).
  • Before that, he was Senior Vice President, Communications & Corporate Affairs at Algeta ASA, where he was responsible for corporate communications and capital markets strategies.
  • His proven track record and wide-ranging financial expertise and relationships will be crucial as Crescendo enters its next phase of growth.\xe2\x80\x9d commented Theodora Harold, CEO of Crescendo.
  • \xe2\x80\x9cWe now have a highly experienced team in place, committed to progressing our pipeline of innovative, first-in-class, T cell enhancing programmes.

Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors

Retrieved on: 
Thursday, February 11, 2021
Algeta

She previously was head of U.S. marketing for Algeta, developer of the first marketed alpha-emitting radiopharmaceutical.

Key Points: 
  • She previously was head of U.S. marketing for Algeta, developer of the first marketed alpha-emitting radiopharmaceutical.
  • "I'm excited to join the board, as I share the Fusion team's passion for improving the lives of cancer patients.
  • The number of seats on the Fusion Board of Directors was increased to eight from seven immediately prior to Dr. Lee's election.
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.

NuCana Appoints Andrew Kay as Board Chairman

Retrieved on: 
Monday, December 21, 2020
Life sciences, Biotechnology, Health sciences, Algeta, Biopharmaceutical

Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics

Key Points: 
  • Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics
    EDINBURGH, United Kingdom, Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Andrew Kay as Chairman of its Board of Directors.
  • We are delighted to welcome Andrew as NuCanas Board Chairman, said Hugh S. Griffith, NuCanas Founder and Chief Executive Officer.
  • Andrew Kay said, I look forward to serving as Chairman of NuCanas Board as we leverage our ProTide technology platform with the aim of developing more efficacious and better tolerated medicines for patients with cancer.
  • Andrew currently serves as Chairman of the Board of NeRRe Therapeutics and Blueberry Therapeutics.

Clarity appoints Dr Gillies O'Bryan-Tear to Chair Newly Formed Global Clinical Development Group

Retrieved on: 
Tuesday, March 31, 2020
Health, Pharmaceutical industry, Clinical research, Algeta, Clinical trial, Pharmacology

SYDNEY, March 31,2020 /PRNewswire/ -- Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O'Bryan-Tear will be chairing Clarity's newly formed Global Clinical Development group.

Key Points: 
  • SYDNEY, March 31,2020 /PRNewswire/ -- Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O'Bryan-Tear will be chairing Clarity's newly formed Global Clinical Development group.
  • Dr O'Bryan-Tear joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and commercial roles.
  • The Global Clinical Development Group will also include other former members of Algeta including Dr Robert Miller, Clarity's Chief Medical Officer, who has provided medical management and clinical development support over his 30-year career in the industry including many years at Algeta.
  • With all of Clarity's SARTATETM, SAR-Bombesin and SAR-bisPSMA products in clinical trials in 2020, Clarity will use the significant experience of the Global Clinical Development Group to optimise the development pathway to market by using the combined clinical development experience of the group, together with Key Opinion Leaders (KOLs) and Clarity's Scientific Advisory Board (SAB).